CENTRAL ADMINISTRATION OF ALLOXAN IMPAIRS GLUCOSE
... Alloxan is selectively taken up into the beta cell by a glucose transporter GLUT2(Gorus et al., 1982; Munday et al., 1993), and GLUT-2 has been recognized as a target molecule for alloxan (Schulte et al., 2002). GLUT-2 is also expressed in the hypothalamus and several other brain regions (Leloup et ...
... Alloxan is selectively taken up into the beta cell by a glucose transporter GLUT2(Gorus et al., 1982; Munday et al., 1993), and GLUT-2 has been recognized as a target molecule for alloxan (Schulte et al., 2002). GLUT-2 is also expressed in the hypothalamus and several other brain regions (Leloup et ...
Pharmacologic Management of Upper Extremity Chronic Nerve Pain
... that I cannot make the nerve the way it was before surgery. Every surgery cuts nerves because there are nerves in every part of the skin. In addition, I counsel that it is not known why most people only develop an area of numbness after surgery but a minority of patients develops nerve pain. I then ...
... that I cannot make the nerve the way it was before surgery. Every surgery cuts nerves because there are nerves in every part of the skin. In addition, I counsel that it is not known why most people only develop an area of numbness after surgery but a minority of patients develops nerve pain. I then ...
2008 Student Paper Competition: Anthony Angelo, Failure Modes
... Failure Modes and Effects Analysis is a proactive approach in the prevention of unanticipated adverse events. The goal of FMEA is to identify ways in which a process can fail and redesign it to prevent or minimize the effects of such failures from reaching a patient. Root Cause Analysis (RCA), anoth ...
... Failure Modes and Effects Analysis is a proactive approach in the prevention of unanticipated adverse events. The goal of FMEA is to identify ways in which a process can fail and redesign it to prevent or minimize the effects of such failures from reaching a patient. Root Cause Analysis (RCA), anoth ...
Effects of psilocybin on hippocampal neurogenesis and extinction of
... et al. 2004). Similarly, other investigators reported that acute ketanserin decreased proliferation, but chronic ketanserin increased proliferation in the DG (Jha et al. 2008). Additionally, no effect on proliferation was observed after DOI or lysergic acid diethylamide (LSD) was administered either ...
... et al. 2004). Similarly, other investigators reported that acute ketanserin decreased proliferation, but chronic ketanserin increased proliferation in the DG (Jha et al. 2008). Additionally, no effect on proliferation was observed after DOI or lysergic acid diethylamide (LSD) was administered either ...
tamoxifen - Cancer Care Ontario
... The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is no ...
... The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is no ...
alertec - Shire Canada
... recent history of myocardial infarction, or unstable angina. Patients with these conditions were not included in the controlled clinical trials. Post-marketing adverse events of ischaemic heart disease, such as myocardial infarction, have been reported in patients with and without a history of cardi ...
... recent history of myocardial infarction, or unstable angina. Patients with these conditions were not included in the controlled clinical trials. Post-marketing adverse events of ischaemic heart disease, such as myocardial infarction, have been reported in patients with and without a history of cardi ...
051800 Daily Interruption of Sedative Infusions in
... in the patients’ care interrupted the infusion of midazolam or propofol and the infusion of morphine simultaneously on a daily basis until the patients were awake and could follow instructions or until they became uncomfortable or agitated and were deemed to require the resumption of sedation. If a ...
... in the patients’ care interrupted the infusion of midazolam or propofol and the infusion of morphine simultaneously on a daily basis until the patients were awake and could follow instructions or until they became uncomfortable or agitated and were deemed to require the resumption of sedation. If a ...
Client information sheet 2 - Veterinary Oncology Consultants
... quality of life during chemotherapy. All anticancer drugs have the potential to produce adverse side effects. However, the side effects that can occur in pets are usually not as severe as those which occur in humans due to the lower doses used. The starting dose of any particular chemotherapy drug u ...
... quality of life during chemotherapy. All anticancer drugs have the potential to produce adverse side effects. However, the side effects that can occur in pets are usually not as severe as those which occur in humans due to the lower doses used. The starting dose of any particular chemotherapy drug u ...
Morphine - Waitemata District Health Board
... If the patient has not had a 24 hour trial of subcut PRN morphine, a total 24 hour dose requirement can often be extrapolated from adding up morphine requirement over the preceding 6 – 18 hours. If a patient has had no subcut morphine to guide dose selection, start with a dose of 10mg over 24 hours ...
... If the patient has not had a 24 hour trial of subcut PRN morphine, a total 24 hour dose requirement can often be extrapolated from adding up morphine requirement over the preceding 6 – 18 hours. If a patient has had no subcut morphine to guide dose selection, start with a dose of 10mg over 24 hours ...
AusPAR: Bendamustine hydrochloride
... use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as per ...
... use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as per ...
Toxic Doses
... • half life elimination (t½) - drugs ( dosing interval), xenobiotics (non-drug) sufficient t1/2 to clear toxin. ...
... • half life elimination (t½) - drugs ( dosing interval), xenobiotics (non-drug) sufficient t1/2 to clear toxin. ...
Optimizing orthodontic treatment in patients taking
... ilar medical treatment efficacy and fewer adverse effects. Similar systemic effect doses for alendronate, risedronate, and ibandronate are noted when comparing daily dosages. A higher systemic dose is given as the time between doses is increased. This can be noted when comparing the increased weekly ...
... ilar medical treatment efficacy and fewer adverse effects. Similar systemic effect doses for alendronate, risedronate, and ibandronate are noted when comparing daily dosages. A higher systemic dose is given as the time between doses is increased. This can be noted when comparing the increased weekly ...
(NSAIDs) classification, diagnosis and management
... hypersensitivity may reach 25.6% (9). Cutaneous manifestations to NSAIDs may affect 0.3% of general population (5), and the prevalence of aspirin hypersensitivity may be as high as 27–35% in patients with chronic urticaria (10). NSAIDs have been reported to be the major (11) or the second group of d ...
... hypersensitivity may reach 25.6% (9). Cutaneous manifestations to NSAIDs may affect 0.3% of general population (5), and the prevalence of aspirin hypersensitivity may be as high as 27–35% in patients with chronic urticaria (10). NSAIDs have been reported to be the major (11) or the second group of d ...
F Part 7.2: Management of Cardiac Arrest
... In one nonrandomized cohort study of out-of-hospital cardiac arrest in adults (LOE 4)28 using a randomized control, administration of atropine and epinephrine by the IV route was associated with a higher rate of ROSC and survival to hospital admission than administration of the drugs by the endotrac ...
... In one nonrandomized cohort study of out-of-hospital cardiac arrest in adults (LOE 4)28 using a randomized control, administration of atropine and epinephrine by the IV route was associated with a higher rate of ROSC and survival to hospital admission than administration of the drugs by the endotrac ...
PBG Report – PBI Feldetrex
... • Incidence of fibromyalgia diagnosis has increased in past few years because : – “ExisBng FDA approved drugs” – “AdverBsement campaigns (especially on TV) for current FDA approved drugs ...
... • Incidence of fibromyalgia diagnosis has increased in past few years because : – “ExisBng FDA approved drugs” – “AdverBsement campaigns (especially on TV) for current FDA approved drugs ...
see p. Mov10 - Viktor`s Notes for the Neurosurgery Resident
... temporary deterioration during the "off" periods, but in most, the severity of camptocormia was unchanged during the "on" and "off" phases. In some patients it is associated with back pains, whereas in others it is painless. It occurs in sporadic PD as well as in postencephalitic and parkin-gene mut ...
... temporary deterioration during the "off" periods, but in most, the severity of camptocormia was unchanged during the "on" and "off" phases. In some patients it is associated with back pains, whereas in others it is painless. It occurs in sporadic PD as well as in postencephalitic and parkin-gene mut ...
Captisol‐enabled™ Busulfan Non‐Confidential Summary October 2014
... Each vial of BUSULFEX contains 60 mg (6 mg/mL) of busulfan, the active ingredient, a white crystalline powder with a molecular formula of CH3SO2O(CH2)4OSO2CH3 and a molecular weight of 246 g/mole. Busulfan is dissolved in N,N‐dimethylacetamide (DMA) 33% vol/vol and Polyethylene Glycol 400, 67% vol ...
... Each vial of BUSULFEX contains 60 mg (6 mg/mL) of busulfan, the active ingredient, a white crystalline powder with a molecular formula of CH3SO2O(CH2)4OSO2CH3 and a molecular weight of 246 g/mole. Busulfan is dissolved in N,N‐dimethylacetamide (DMA) 33% vol/vol and Polyethylene Glycol 400, 67% vol ...
Cancer Pain - International Pain School
... reduce the dosage and the side effects of the single drug ...
... reduce the dosage and the side effects of the single drug ...
Stimulant prescribing code explanatory notes
... The regulatory control framework for stimulants requires prescribers initiating treatment with a stimulant to register with the Department of Health and obtain a Stimulant Prescriber Number. Authorised practitioners can initiate treatment for patients who meet the criteria set out in the Stimulant P ...
... The regulatory control framework for stimulants requires prescribers initiating treatment with a stimulant to register with the Department of Health and obtain a Stimulant Prescriber Number. Authorised practitioners can initiate treatment for patients who meet the criteria set out in the Stimulant P ...
zoloft - Medsafe
... to 17 years. More than 250 paediatric OCD patients have been exposed to sertraline in completed and ongoing studies. The safety profile of sertraline in these paediatric studies is comparable to that observed in adult OCD studies. The administration of sertraline to paediatric OCD patients (aged 13 ...
... to 17 years. More than 250 paediatric OCD patients have been exposed to sertraline in completed and ongoing studies. The safety profile of sertraline in these paediatric studies is comparable to that observed in adult OCD studies. The administration of sertraline to paediatric OCD patients (aged 13 ...
Intranasal (IN) Medication Administration MBED Clinical Practice
... CLINICAL PHARMACOLOGY: Dexmedetomidine is a selective α2-adrenergic receptor agonist that has sedative, analgesic, anesthetic and sympatholytic properties. Its effects are thought to be linked to the activation of G-proteins by the alpha2a receptors in the brainstem, which results in the inhibition ...
... CLINICAL PHARMACOLOGY: Dexmedetomidine is a selective α2-adrenergic receptor agonist that has sedative, analgesic, anesthetic and sympatholytic properties. Its effects are thought to be linked to the activation of G-proteins by the alpha2a receptors in the brainstem, which results in the inhibition ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.